Parnate Related Published Studies
Well-designed clinical trials related to Parnate (Tranylcypromine)
Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. [2010.02.28]
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. [2006.09]
Well-designed clinical trials possibly related to Parnate (Tranylcypromine)
Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled
randomized trials. [2011]
Other research related to Parnate (Tranylcypromine)
[Tranylcypromine for chronic therapy-resistant agoraphobia with panic disorder and recurrent depressive disorder]. [2010.10]
Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. [2008.11]
Withdrawal from high-dose tranylcypromine. [2008.03]
Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. [2007.05]
Tranylcypromine: new perspectives on an "old" drug. [2006.08]
Other possibly related research studies
New findings from the Bipolar Collaborative Network: clinical implications for therapeutics. [2006.12]
Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. [2006.08]
Transdermal selegiline: the new generation of monoamine oxidase inhibitors. [2006.05]
The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. [2005.10]
[Life-threatening serotonin syndrome following a single dose of a serotonin reuptake inhibitor during maintenance therapy with a monoamine oxidase inhibitor] [2006.05.13]
Bipolar depression: issues in diagnosis and treatment. [2005.09]
Chronic administration of the delta opioid receptor agonist (+)BW373U86 and antidepressants on behavior in the forced swim test and BDNF mRNA expression in rats. [2005.11]
Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. [2005.07]
Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. [2005.12]
Potential of [11C]DASB for measuring endogenous serotonin with PET: binding studies. [2005.02]
Motor cortex excitability after vagus nerve stimulation in major depression. [2007.04]
Running exercise- and antidepressant-induced increases in growth and survival-associated signaling molecules are IGF-dependent. [2007.04]
Reduced evoked fos expression in activity-related brain regions in animal models of behavioral depression. [2007.08.15]
Possible involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride. [2007.08.13]
[The treatment of psychotic depression in patients insufficiently responsive to conventional medication and electroconvulsive therapy; what are the options?] [2008]
The guinea pig forced swim test as a new behavioral despair model to characterize potential antidepressants. [2007.11]
Rivastigmine-induced dystonia. [2007.12.01]
Antidepressant-Associated Mood Elevations in Bipolar II Disorder Compared With Bipolar I Disorder and Major Depressive Disorder: A Systematic Review and Meta-Analysis. [2008.07.15]
Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression. [2008.04]
Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. [2008.06]
Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. [2008.10]
Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-thienyl)pyrazoline derivatives. [2008.11]
STAR*D: revising conventional wisdom. [2009]
[Irreversible, non-selective monoamine oxidase inhibitors] [2009.04.16]
Antidepressant activity of curcumin: involvement of serotonin and dopamine system. [2008.12]
Transport of phenylethylamine at intestinal epithelial (Caco-2) cells: mechanism and substrate specificity. [2010.02]
limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. [2010.08]
STAR*D: revising conventional wisdom. [2009.08.01]
MAO-inhibitors in Parkinson's Disease. [2011.03]
Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. [2011.04]
Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. [2010.10.04]
|
